Grant: Undergraduate Student Research Awards (USRA)
University of Toronto
$6,000.00
Psilocybin Assisted Psychotherapy for Bipolar Depression: An fMRI Emotional-Processing Pilot Study
EF 2023-24
Résumé
Our incomplete understanding of the neurobiology of bipolar disorder (BD) has been a major barrier to developing innovative, hypothesis-driven interventions. Overactivation of the amygdala has been proposed to be one key mechanism whereby BD is associated with increased emotional reactivity causing recurrent mood episodes. Accordingly, many treatments target this network to reduce the activity of the amygdala. Psilocybin has been associated with increased amygdala reactivity in response to emotional stimuli in unipolar depression, which predicted greater antidepressant effects. To explore the role of the amygdala in BD, we propose an emotional-processing fMRI pilot study, wherein twenty participants with moderate to severe treatment resistant bipolar II depression (TRBD) will receive one 25 mg dose of oral psilocybin with supportive psychotherapy. Our primary objective is to determine if increased amygdala activity during emotional stimuli post-psilocybin treatment is associated with antidepressant effects in individuals with TRBD. Secondary objectives include assessing feasibility, safety and clinical outcomes. Resting state and task related fMRI analysis will be completed at baseline, one day after the dosing session (Day 1; primary imaging endpoint) and one-month post-dose (secondary endpoint to evaluate sustained fMRI changes). The association of right amygdala activity during negative emotional stimuli in a facial affect task on Day 1 with acute antidepressant effects will be the primary outcome of interest, to determine if increased amygdala activity is associated with clinical benefits. As the first study evaluating neurobiological and clinical effects of psilocybin in BD, the findings have potential to have a major impact for the field.
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486939
Name
Idd Hanan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Psilocybin Assisted Psychotherapy for Bipolar Depression: An fMRI Emotional-Processing Pilot Study
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Toronto
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Amygdala; Antipressant; Bipolar; Clinical; Depression; Emotional; Interventions; Neurobiology
Abstract
Our incomplete understanding of the neurobiology of bipolar disorder (BD) has been a major barrier to developing innovative, hypothesis-driven interventions. Overactivation of the amygdala has been proposed to be one key mechanism whereby BD is associated with increased emotional reactivity causing recurrent mood episodes. Accordingly, many treatments target this network to reduce the activity of the amygdala. Psilocybin has been associated with increased amygdala reactivity in response to emotional stimuli in unipolar depression, which predicted greater antidepressant effects. To explore the role of the amygdala in BD, we propose an emotional-processing fMRI pilot study, wherein twenty participants with moderate to severe treatment resistant bipolar II depression (TRBD) will receive one 25 mg dose of oral psilocybin with supportive psychotherapy. Our primary objective is to determine if increased amygdala activity during emotional stimuli post-psilocybin treatment is associated with antidepressant effects in individuals with TRBD. Secondary objectives include assessing feasibility, safety and clinical outcomes. Resting state and task related fMRI analysis will be completed at baseline, one day after the dosing session (Day 1; primary imaging endpoint) and one-month post-dose (secondary endpoint to evaluate sustained fMRI changes). The association of right amygdala activity during negative emotional stimuli in a facial affect task on Day 1 with acute antidepressant effects will be the primary outcome of interest, to determine if increased amygdala activity is associated with clinical benefits. As the first study evaluating neurobiological and clinical effects of psilocybin in BD, the findings have potential to have a major impact for the field.
Competitiondate
202305
Approvedterm2
0 yr 6 mths
Pinamesdelim
Idd, Hanan
Approvedterm
0 an 6 mois
Cihrcontribution2
~ $6,000~ $0~